We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+6.78%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$150M
AUM Growth
-$10.7M
Cap. Flow
-$11.4M
Cap. Flow %
-7.61%
Top 10 Hldgs %
46.24%
Holding
65
New
12
Increased
10
Reduced
12
Closed
16

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$3.24M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$3.07M
3
OCUL icon
Ocular Therapeutix
OCUL
+$2.58M
4
MGNX icon
MacroGenics
MGNX
+$2.53M
5
NGNE icon
Neurogene
NGNE
+$2.34M

Top Sells

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$5.29M
2
ASRT
Assertio
ASRT
+$4.53M
3
GERN icon
Geron
GERN
+$3.87M
4
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$3.38M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$2.91M

Sector Composition

Rank Sector Weight
1 Healthcare 91.89%
2 Miscellaneous 8.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTK
26
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.04M 1.36%
+146,700
New +$2.16M
NBRV
27
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$2.02M 1.35%
1,080
-15
-1% -$30.2K
NGNE icon
28
Neurogene
NGNE
$758M
$1.95M 1.3%
+14,750
New +$2.34M
EGRX
29
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$1.94M 1.3%
50,000
-10,000
-17% -$416K
ZGNX
30
DELISTED
Zogenix, Inc.
ZGNX
$1.93M 1.29%
240,000
– –
TRIL
31
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.75M 1.17%
195,000
– –
MCRB icon
32
Seres Therapeutics
MCRB
$49.7M
$1.67M 1.12%
+2,875
New +$1.69M
CTMX icon
33
CytomX Therapeutics
CTMX
$745M
$1.63M 1.09%
+160,000
New +$1.82M
TNXP icon
34
Tonix Pharmaceuticals
TNXP
$233M
– –
0
– –
AFMD
35
DELISTED
Affimed
AFMD
$1.48M 0.99%
59,500
-1,500
-2% -$54.8K
INNL
36
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$1.46M 0.98%
+265,000
New +$2.17M
CYTO
37
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.43M 0.95%
4
– –
OCUL icon
38
Ocular Therapeutix
OCUL
$2.38B
$1.29M 0.86%
+260,000
New +$2.58M
KA
39
DELISTED
Kineta, Inc. Common Stock
KA
$1.27M 0.85%
+750
New +$1.37M
CORI
40
DELISTED
Corium International, Inc.
CORI
$1.25M 0.83%
360,000
– –
TENX icon
41
Tenax Therapeutics
TENX
$82M
$1.19M 0.79%
15
-1
-6% -$83.4K
TGTX icon
42
TG Therapeutics
TGTX
$8.53B
$1.06M 0.71%
175,000
-240,000
-58% -$1.95M
EVOK
43
DELISTED
Evoke Pharma
EVOK
$891K 0.6%
903
– –
NDRM
44
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$853K 0.57%
52,500
+14,000
+36% +$236K
CDTX
45
DELISTED
Cidara Therapeutics
CDTX
$443K 0.3%
+2,150
New +$520K
ADAP
46
DELISTED
Adaptimmune Therapeutics
ADAP
$326K 0.22%
40,000
-135,300
-77% -$1.27M
BLRX
47
BioLineRX
BLRX
$12.1M
$223K 0.15%
417
– –
ACRS icon
48
Aclaris Therapeutics
ACRS
$907M
– –
-18,000
Closed -$341K
ASRT
49
DELISTED
Assertio
ASRT
– –
-5,417
Closed -$4.53M
GERN icon
50
Geron
GERN
$983M
– –
-1,325,000
Closed -$3.87M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q2 2016 Portfolio in Review

As of Q2 2016, Opaleye Management held 65 positions worth $150M, down 6.6% from $160M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Opaleye Management withdrew a net $11.4M in Q2 2016, closing 16 positions and reducing 12 holdings. Its most notable exit was Sage Therapeutics, an estimated $5.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 88% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Horizon Therapeutics Public Limited Company Ordinary Shares worth $3.29M.

  • Opaleye Management's largest Q2 2016 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 200,000 shares worth $3.29M.
  • Opaleye Management added most to Aevi Genomic Medicine Inc in Q2 2016, an estimated $2.06M increase.
  • Opaleye Management's biggest Q2 2016 reduction was Ultragenyx Pharmaceutical, cutting an estimated $2.91M.
  • Opaleye Management fully exited Sage Therapeutics in Q2 2016, selling an estimated $5.29M.
  • Opaleye Management's ten largest holdings make up 46% of its $150M portfolio in Q2 2016.
  • Opaleye Management opened 12 new positions and closed 16 in Q2 2016.
  • Opaleye Management's portfolio value fell 6.6% quarter-over-quarter to $150M.

Based on Opaleye Management's 13F filing for Q2 2016, filed 12 Aug 2016.